Inclusion Criteria:  Males or females, of any race, aged ≥ 18 years. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0- 2. Sufficient bone marrow function, hepatic function and Coagulation function. Patients must have measurable disease per disease-specific response criteria. Have histologically confirmed R/R CLL,SLL,MCL,Non-GCB DLBCL,FL(grade 1- 3a),MZL,WM. Received at least 1 prior systemic therapy(MCL no more than 5 lines of treatment) and have no other therapies known to provide clinical benefit. After the most recent treatment regimen, it is confirmed that PR has not been achieved, or there is confirmed progressive disease. Must require systemic therapy. The pregnancy test (urine or serum) of female subjects of childbearing potential shall be negative before enrollment. Female subjects of childbearing potential and fertile male subjects shall adopt one of the following highly effective contraception measures during the entire study and within 90 days after the study treatment is ended: abstinence, intrauterine device, or hormonal contraceptives beginning at least 3 months before the first dose of IMP.Male subjects are prohibited from donating sperm from the start of study treatment to 90 days after the end of treatment.  Exclusion Criteria:  Subjects with central nervous system involvement. Subjects with histopathological transformation. Receipt of allogeneic hematopoietic stem cell transplantation ≤ 180 days before the start of study treatment administration on Cycle 1, Day 1, unless the subject is no longer on immunosuppressant medication. History of autologous hematopoietic stem cell transplantation within 12 weeks (84 days) before the start of study treatment. Continuous immunosuppressive therapy, including systemic (such as intravenous or oral) treatment with corticosteroids for the underlying diseases within 2 weeks before the first dose. Received any chemotherapy, biological therapy (such as monoclonal antibodies), immunotherapy, Chinese herbal medicines with anti-tumor efficacy, or other anti-tumor treatments within 4 weeks before the first use of HSK29116. The time interval from the last dose of BTK inhibitor or experimental small molecule drug to the first dose of the IMP is 5 times shorter than the half-life of the previously used drug. Previously developed toxicity due to anticancer treatment that did not resolve to Grade ≤ 1 (as per NCI-CTCAE 5.0), except for AEs not constituting a safety risk as assessed by the investigator. A history of other malignant tumors within 2 years before enrollment, except for basal cell carcinoma or skin squamous cell carcinoma having been adequately treated, or without disease for ≥ 2 years or with other types of cancer with the survival time of greater than 2 years. Subjects with breast or prostate cancer who are on maintenance hormonal therapies following therapeutic procedures with curative intent are permitted. Uncontrolled systemic active infections, or other infections or still on intravenous anti-infection treatment. Underwent major surgery in the past 4 weeks. Known infection with human immunodeficiency virus, or serologic status reflecting active hepatitis B or C infection. Subjects with severe cardiovascular diseases within 6 months before screening. Left Ventricular Ejection Fraction < 50% based on either echocardiogram or multigated acquisition (MUGA) scan. QTcF ≥ 450 msecs for males and QTcF ≥ 470 msec for females or other significant ECG abnormalities. Clinically significant gastrointestinal abnormalities that may affect the intake, transport, or absorption of drugs. Requiring or received anticoagulant therapy with warfarin or equivalent vitamin K antagonists (such as phenprocoumon) within 7 days before the first study treatment. Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura. Known history of bleeding diathesis. A history of stroke or intracranial hemorrhage within 6 months before the first study treatment. Use of CYP3A4 inhibitor or inducer within 7 days before the first study treatment, or using of sensitive substrates metabolized by CYP3A4/CYP2B6.